Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 27 Triple Negative Breast Neoplasms 9 Sarcoma 5 Neoplasm Metastasis 4 Liposarcoma 3 Urinary Bladder Neoplasms 2 Leiomyosarcoma 2 Inflammatory Breast Neoplasms 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Refractory Solid Tumors 1 Recurrence 1 Metastatic HER2-positive Breast Cancer 1 Inoperable Locally Advanced HER2-Negative Breast Cancer 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Colorectal Neoplasms 1 Brest Cancer 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

eribulin 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Brest Cancer × eribulin × 1 year × Clear all

NCT07333937 2026-01-12

NETHER

Xijing Hospital

Phase 2 Not yet recruiting

Brest Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡